Purpose of review In this review, we emphasize up-to-date practical cytogenetic and
molecular aspects of chronic myeloid leukemia (CML) and summarize current knowledge on …

Despite the remarkable results achieved with imatinib for the treatment of chronic myeloid
leukaemia, the emergence of resistance to this tyrosine kinase inhibitor has become a …

In the past few years, international treatment guidelines for chronic myeloid leukaemia have
incorporated recommendations for attempting discontinuation of treatment with tyrosine …

The expansion of a leukemia clone bearing a Bcr-Abl kinase domain mutation is associated
with acquired resistance to imatinib and may also predict disease progression in patients …

Chronic myeloid leukemia (CML) has long served as a paradigm for generating new insights
into the cellular origin, pathogenesis and improved approaches to treating many types of …

The natural history of chronic myeloid leukemia (CML) progresses from a relatively benign
chronic phase into a fatal blast crisis, which resembles acute leukemia, but is incurable by …

The constitutively active BCR-ABL1 tyrosine kinase, found in t (9; 22)(q34; q11)
chromosomal translocation-derived leukemia, initiates an extremely complex signaling …

C-abl oncogene 1, nonreceptor tyrosine kinase (ABL1) kinase inhibitors such as imatinib
mesylate (imatinib) are effective in managing chronic myeloid leukemia (CML) but incapable …

Abstract Purpose of Review Chronic myeloid leukemia (CML) patients with constitutive
activity of BCR-ABL1 oncoprotein frequently derive significant clinical benefits from tyrosine …

Recent studies have identified primitive, malignant stem cells which have entered the G0-
phase of the cell cycle to become'quiescent'and which are present, in small numbers, in all …